Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X


Journal

Chemical communications (Cambridge, England)
ISSN: 1364-548X
Titre abrégé: Chem Commun (Camb)
Pays: England
ID NLM: 9610838

Informations de publication

Date de publication:
05 Dec 2019
Historique:
pubmed: 23 11 2019
medline: 15 1 2020
entrez: 23 11 2019
Statut: ppublish

Résumé

BCL-XL, an anti-apoptotic BCL-2 family protein, plays a key role in cancer cell survival. However, the potential of BCL-XL as an anti-cancer target has been hampered by the on-target platelet toxicity because platelets depend on BCL-XL to maintain their viability. Here we report the development of a PROTAC BCL-XL degrader, XZ424, which has increased selectivity for BCL-XL-dependent MOLT-4 cells over human platelets compared with conventional BCL-XL inhibitors. This proof-of-concept study demonstrates the potential of utilizing a PROTAC approach to achieve tissue selectivity.

Identifiants

pubmed: 31754664
doi: 10.1039/c9cc07217a
pmc: PMC7057339
mid: NIHMS1554820
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
CRBN protein, human 0
Isoquinolines 0
bcl-X Protein 0
Thalidomide 4Z8R6ORS6L
pomalidomide D2UX06XLB5
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

14765-14768

Subventions

Organisme : NCI NIH HHS
ID : R01 CA211963
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA219836
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA223371
Pays : United States
Organisme : NIH HHS
ID : S10 OD021758
Pays : United States

Références

J Med Chem. 2018 Jan 25;61(2):462-481
pubmed: 28339196
PLoS One. 2015 Mar 26;10(3):e0120913
pubmed: 25811469
Onco Targets Ther. 2018 Oct 23;11:7301-7314
pubmed: 30425521
J Med Chem. 2019 Jun 13;62(11):5522-5540
pubmed: 31117518
Cell Death Differ. 2015 Jul;22(7):1071-80
pubmed: 25952548
Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10
pubmed: 26593377
Drugs. 2016 Jun;76(9):979-87
pubmed: 27260335
J Med Chem. 2019 Sep 12;62(17):8152-8163
pubmed: 31389699
J Med Chem. 2019 Feb 14;62(3):1420-1442
pubmed: 30990042
Cancer Discov. 2017 Feb;7(2):165-176
pubmed: 27979832
Chem Biol. 2015 Jun 18;22(6):755-63
pubmed: 26051217
Science. 2015 Jun 19;348(6241):1376-81
pubmed: 25999370
Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63
pubmed: 24355989
Nat Rev Cancer. 2002 Apr;2(4):277-88
pubmed: 12001989
J Med Chem. 2018 Jan 25;61(2):444-452
pubmed: 29144739
ACS Med Chem Lett. 2014 Aug 26;5(10):1088-93
pubmed: 25313317
Nat Rev Drug Discov. 2017 Feb;16(2):101-114
pubmed: 27885283
Nat Chem Biol. 2013 Jun;9(6):390-7
pubmed: 23603658
Nat Rev Cancer. 2016 Feb;16(2):99-109
pubmed: 26822577
FEBS J. 2016 Jul;283(14):2661-75
pubmed: 26293580
Chem Commun (Camb). 2019 Jan 2;55(3):369-372
pubmed: 30540295
Oncogene. 2007 Feb 26;26(9):1324-37
pubmed: 17322918
Angew Chem Int Ed Engl. 2017 May 15;56(21):5738-5743
pubmed: 28418626
Chem Commun (Camb). 2017 Jul 4;53(54):7577-7580
pubmed: 28636052
J Med Chem. 2019 Jan 24;62(2):448-466
pubmed: 30525597
Cell Death Differ. 2018 Jan;25(1):65-80
pubmed: 29149100
PLoS One. 2013 Dec 11;8(12):e81809
pubmed: 24349131
Expert Opin Ther Targets. 2013 Jan;17(1):61-75
pubmed: 23173842
Aging (Albany NY). 2017 Mar 8;9(3):955-963
pubmed: 28273655
Nat Med. 2016 Jan;22(1):78-83
pubmed: 26657143
J Am Chem Soc. 2018 Dec 12;140(49):17019-17026
pubmed: 30444612
ACS Chem Biol. 2019 Mar 15;14(3):342-347
pubmed: 30807093
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8554-9
pubmed: 11438690
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Adv Med. 2014;2014:943648
pubmed: 26556430
Curr Opin Chem Biol. 2017 Aug;39:133-142
pubmed: 28735187
Cell. 2007 Mar 23;128(6):1173-86
pubmed: 17382885
Cell Death Differ. 2007 May;14(5):943-51
pubmed: 17205078
BMC Genomics. 2013 Jan 16;14:1
pubmed: 23323973
J Clin Invest. 2018 Apr 2;128(4):1247-1254
pubmed: 29608140
J Med Chem. 2017 Feb 9;60(3):821-838
pubmed: 27749061
Nat Chem Biol. 2019 Jul;15(7):672-680
pubmed: 31178587
J Med Chem. 2019 Jan 24;62(2):699-726
pubmed: 30540463
J Med Chem. 2019 Jan 24;62(2):941-964
pubmed: 30629437
Sci Transl Med. 2015 Mar 18;7(279):279ra40
pubmed: 25787766
Mol Cancer Ther. 2012 Apr;11(4):1026-35
pubmed: 22302098
J Med Chem. 2018 Jan 25;61(2):482-491
pubmed: 28379698
Nat Commun. 2016 Apr 06;7:11190
pubmed: 27048913
Chem Commun (Camb). 2019 Feb 26;55(18):2704-2707
pubmed: 30758029

Auteurs

Xuan Zhang (X)

Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1333 Center Drive, Gainesville, FL 32610, USA. zhengg@cop.ufl.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH